1.5 Abstract in rivista

1.5 Abstract in rivista: [1829] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 141 a 160 di 1.829

Does an escaping object look faster? Animacy induced speed overestimation in chasing events

2019-01-01 Parovel, G.; Guidi, S.

Speed Overestimation in Chasing Events

2018-01-01 Parovel, G.; Guidi, S.

Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients

2018-01-01 Ravaioli, F; Dajti, E; Colecchia, A; Alemanni, V; Marasco, G; Tamé, M; Azzaroli, F; Brillanti, S; Mazzella, G; Festi, D

Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials

2009-01-01 O'Day, S; Weber, J; Lebbe, C; Maio, M; Pehamberger, H; Harmankaya, K; Siegel, J; Hoos, A; Humphrey, R; Wolchok, J

Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy

2009-01-01 Danielli, R; Queirolo, P; Testori, A; Plummer, R; Razi, E; Sileni Chiarion, V; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M

Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs)

2009-01-01 Grob, J; Hamid, O; Wolchok, J; Maio, M; Neyns, B; Thomas, L; de Pril, V; Ibrahim, R; O'Day, S; Lebbe, C

Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels

2009-01-01 Smylie, M; Francis, S; Neyns, B; Maio, M; Minor, D; Verschraegen, C; Chin, K; Ibrahim, R; Hoos, A; Schadendorf, D

MAGE-A3 Antigen-specific Cancer Immunotherapeutic in Metastatic Melanoma: Final Results of a Randomized Open-label Phase II Study of the EORTC Melanoma Group (16032-18031)

2009-01-01 Dreno, B; Mortier, L; Robert, C; Chiarion Sileni, V; Testorill, A; Maio, M; Awada, A; Lehmann, F; Kruit, W

Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients

2009-01-01 DI GIACOMO, ANNA MARIA; Danielli, R; Calabro, L; Bertocci, E; Nannicini, C; Miracco, C; Biagioli, M; Mazzei, Ma; Altomonte, M; Maio, M

P7 Treatment with lpllimumab brings an advantage with reference to long-term survival: reflection rate after 24-months of patients with advanced melanoma from 3 phase II studies with 10mg/kg lpillimumab

2009-01-01 O'Day, Sj; Schadendorf, D; Weber, J; Lebbe, C; Maio, M; Pehamberger, H; Harmankaya, K; Siegel, J; Hoos, A; Humphrey, R; Wolchok, J

P10 lpillimumab in a dose of 10mg/kg improves in patients sith melanoma in stage M1c the disease progression independent of lactat-dehydrogenase (LDH) level

2009-01-01 Smylie, M; Kaehler, Kc; Francis, S; Nyens, B; Maio, M; Minor, D; Verschraegen, C; Chin, K; Ibrahim, R; Hoos, A; Schadendorf, D

Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials

2009-01-01 Maio, M; Lebbe, C; Sileni Chiarion, V; Siegel, J; Hoos, A; Humphrey, R; O'Day, S; Wolchok, J; Weber, J; Harmankaya, K

Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors

2009-01-01 Schadendorf, D; Wolchok, J; Neyns, B; Lebbe, C; Harmankaya, K; Verschraegen, C; Chin, K; de Pril, V; Hoos, A; Maio, M

Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma

2010-01-01 Wolchok, Jd; Weber, Js; Hamid, O; Lebbe, C; Maio, M; Schadendorf, D; de Pril, V; Ibrahim, R; Hoos, A; O'Day, Sj

Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide

2010-01-01 Coral, S; Sigalotti, L; Parisi, G; Colizzi, F; Fratta, E; Nicolay, Hjm; Taverna, P; Maio, M

Health-Care resource Utilization in advanced melanoma: an analysis from the MELODY observational study

2010-01-01 Lorigan, P; Maio, M; Middleton, M; Testori, A; Bedane, C; van Baardewijk, M; Konto, C; Dueymes, A; Lebbe, C

Immunobiologic Activity of the Demethylating Dinucleotide SGI-110

2010-01-01 Coral, S; Sigalotti, L; Fonsatti, E; Parisi, G; Colizzi, F; Nicolay, Hj; Taverna, P; Maio, M

Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients

2010-01-01 Danielli, R; Queirolo, P; Testori, A; Plummer, R; Sileni Chiarion, V; Altomonte, M; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M

Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients

2011-01-01 Weide, B; Zelba, H; Derhovanessian, E; Pflugfelder, A; Schadendorf, D; de Vries, J; Maio, M; Garbe, C; Pawelec, G

A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial

2011-01-01 DI GIACOMO, ANNA MARIA; Ascierto, Pa; Pittiglio, E; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Parmiani, G; Maio, M

Titolo	Data di pubblicazione	Autore(i)	Abstract
Does an escaping object look faster? Animacy induced speed overestimation in chasing events	1-gen-2019	Parovel, G.; Guidi, S.	-
Speed Overestimation in Chasing Events	1-gen-2018	Parovel, G.; Guidi, S.	-
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients	1-gen-2018	Ravaioli, F; Dajti, E; Colecchia, A; Alemanni, V; Marasco, G; Tamé, M; Azzaroli, F; Brillanti, S; Mazzella, G; Festi, D	-
Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials	1-gen-2009	O'Day, S; Weber, J; Lebbe, C; Maio, M; Pehamberger, H; Harmankaya, K; Siegel, J; Hoos, A; Humphrey, R; Wolchok, J	-
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy	1-gen-2009	Danielli, R; Queirolo, P; Testori, A; Plummer, R; Razi, E; Sileni Chiarion, V; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M	-
Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs)	1-gen-2009	Grob, J; Hamid, O; Wolchok, J; Maio, M; Neyns, B; Thomas, L; de Pril, V; Ibrahim, R; O'Day, S; Lebbe, C	-
Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels	1-gen-2009	Smylie, M; Francis, S; Neyns, B; Maio, M; Minor, D; Verschraegen, C; Chin, K; Ibrahim, R; Hoos, A; Schadendorf, D	-
MAGE-A3 Antigen-specific Cancer Immunotherapeutic in Metastatic Melanoma: Final Results of a Randomized Open-label Phase II Study of the EORTC Melanoma Group (16032-18031)	1-gen-2009	Dreno, B; Mortier, L; Robert, C; Chiarion Sileni, V; Testorill, A; Maio, M; Awada, A; Lehmann, F; Kruit, W	-
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients	1-gen-2009	DI GIACOMO, ANNA MARIA; Danielli, R; Calabro, L; Bertocci, E; Nannicini, C; Miracco, C; Biagioli, M; Mazzei, Ma; Altomonte, M; Maio, M	-
P7 Treatment with lpllimumab brings an advantage with reference to long-term survival: reflection rate after 24-months of patients with advanced melanoma from 3 phase II studies with 10mg/kg lpillimumab	1-gen-2009	O'Day, Sj; Schadendorf, D; Weber, J; Lebbe, C; Maio, M; Pehamberger, H; Harmankaya, K; Siegel, J; Hoos, A; Humphrey, R; Wolchok, J	-
P10 lpillimumab in a dose of 10mg/kg improves in patients sith melanoma in stage M1c the disease progression independent of lactat-dehydrogenase (LDH) level	1-gen-2009	Smylie, M; Kaehler, Kc; Francis, S; Nyens, B; Maio, M; Minor, D; Verschraegen, C; Chin, K; Ibrahim, R; Hoos, A; Schadendorf, D	-
Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials	1-gen-2009	Maio, M; Lebbe, C; Sileni Chiarion, V; Siegel, J; Hoos, A; Humphrey, R; O'Day, S; Wolchok, J; Weber, J; Harmankaya, K	-
Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors	1-gen-2009	Schadendorf, D; Wolchok, J; Neyns, B; Lebbe, C; Harmankaya, K; Verschraegen, C; Chin, K; de Pril, V; Hoos, A; Maio, M	-
Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma	1-gen-2010	Wolchok, Jd; Weber, Js; Hamid, O; Lebbe, C; Maio, M; Schadendorf, D; de Pril, V; Ibrahim, R; Hoos, A; O'Day, Sj	-
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide	1-gen-2010	Coral, S; Sigalotti, L; Parisi, G; Colizzi, F; Fratta, E; Nicolay, Hjm; Taverna, P; Maio, M	-
Health-Care resource Utilization in advanced melanoma: an analysis from the MELODY observational study	1-gen-2010	Lorigan, P; Maio, M; Middleton, M; Testori, A; Bedane, C; van Baardewijk, M; Konto, C; Dueymes, A; Lebbe, C	-
Immunobiologic Activity of the Demethylating Dinucleotide SGI-110	1-gen-2010	Coral, S; Sigalotti, L; Fonsatti, E; Parisi, G; Colizzi, F; Nicolay, Hj; Taverna, P; Maio, M	-
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients	1-gen-2010	Danielli, R; Queirolo, P; Testori, A; Plummer, R; Sileni Chiarion, V; Altomonte, M; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M	-
Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients	1-gen-2011	Weide, B; Zelba, H; Derhovanessian, E; Pflugfelder, A; Schadendorf, D; de Vries, J; Maio, M; Garbe, C; Pawelec, G	-
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial	1-gen-2011	DI GIACOMO, ANNA MARIA; Ascierto, Pa; Pittiglio, E; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Parmiani, G; Maio, M	-

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 141 a 160 di 1.829

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext1288
reserved442
open83
internalNetwork13
partially open3